What is the appropriate initial management and workup for a newborn with neonatal onset epilepsy?

Management of Neonatal Onset Epilepsy

Phenobarbital at 20 mg/kg IV is the first-line treatment for neonatal seizures regardless of etiology (except when channelopathy is suspected based on family history), with moderate-quality evidence showing 80% seizure control compared to only 28% with levetiracetam. 1

Immediate Diagnostic Approach

EEG Confirmation is Essential

• Obtain continuous EEG (cEEG) or amplitude-integrated EEG (aEEG) immediately - this is the gold standard for diagnosis, as most neonatal seizures are electrographic-only without clinical manifestations 1
• Only focal clonic and focal tonic seizures can be diagnosed clinically; all other seizure types require EEG confirmation 1
• Clinical observation alone systematically underestimates true seizure burden 2

Urgent Etiological Workup

Prioritize identifying treatable causes:

• Metabolic panel: glucose, calcium, magnesium, sodium - correct immediately if abnormal
• Neuroimaging (MRI brain): essential for identifying HIE, stroke, hemorrhage, or structural malformations 3
• Infection workup: lumbar puncture, blood cultures if sepsis/meningitis suspected
• Genetic testing: epilepsy panel or trio whole exome sequencing, particularly if no acute provoked cause identified 3

Pharmacological Management Algorithm

First-Line Treatment

Phenobarbital 20 mg/kg IV for most etiologies (HIE, stroke, hemorrhage) 1

• If seizures continue after 15 minutes, give additional 20 mg/kg 1
• Achieves 80% seizure cessation with sustained 24-hour freedom 1
• Important caveat: Hypotension occurs in 17% of cases - monitor blood pressure closely 1

Exception - Family History of Channelopathy:

• If positive family history suggests KCNQ2/KCNQ3 variants (self-limited familial neonatal epilepsy), use phenytoin or carbamazepine (sodium channel blockers) as first-line instead 1
• 91% expert consensus supports this approach 1

Second-Line Treatment (if first-line fails)

For most etiologies (HIE, stroke, hemorrhage):

• Phenytoin OR levetiracetam 1
• Alternative options: midazolam or lidocaine (less favorable) 1

If channelopathy suspected (based on clinical/EEG features, not just family history):

• Use sodium channel blocker (phenytoin or carbamazepine) 1

If cardiac disorders present:

• Prefer levetiracetam as second-line to avoid cardiac effects of other agents 1

Pyridoxine Trial - Critical Safety Net

Administer pyridoxine trial if:

1. Clinical features or EEG characteristics suggest vitamin B6-dependent epilepsy 1
2. Seizures unresponsive to second-line ASM without identified etiology 1

• Do not delay treatment to collect diagnostic samples - pyridoxine trial can be started first 1
• If pyridoxine fails and B6-dependent epilepsy still suspected, trial pyridoxal 5'-phosphate (PLP) 1
• Partial or transient response to conventional ASM does not rule out B6-dependent epilepsy 1

Duration of Treatment

Discontinue ASM before hospital discharge if:

• Acute provoked seizures have ceased (electroclinical or electrographic) 1
• No evidence of neonatal-onset epilepsy syndrome 1
• This applies regardless of MRI or EEG background abnormalities 1

This represents a major shift from prior guidelines and is supported by evidence showing no difference in neurodevelopment or epilepsy risk at 24 months whether ASM was continued or discontinued at discharge 1

Common Pitfalls to Avoid

1. Relying on clinical observation alone - up to 50% of neonatal seizures are purely electrographic without clinical signs 2

2. Delaying phenobarbital in favor of levetiracetam - despite levetiracetam's better safety profile, phenobarbital has superior efficacy (RR = 0.35,95% CI 0.22-0.56) 1

3. Continuing ASM long-term for acute provoked seizures - this does not improve neurodevelopmental outcomes and unnecessarily exposes infants to potential adverse effects 1

4. Missing vitamin B6-dependent epilepsy - always trial pyridoxine in refractory cases without identified etiology 1

5. Using phenobarbital when channelopathy suspected - sodium channel blockers are more effective for KCNQ2/3-related seizures 1

Prognostic Considerations

Etiology is the primary determinant of outcome, not seizure burden alone 2. However, reducing electrographic seizure burden (including subclinical seizures) may be associated with improved neurodevelopmental outcomes based on indirect evidence 1. This underscores the importance of EEG-confirmed seizure control rather than just clinical cessation.

Each neonatal unit should have a standardized treatment pathway for managing neonatal seizures 1